#layerDDE5EB1980492BAD22E4D15A310DB34C .search_btn {border: 0px solid #fff;border-radius: 0px;color: #fff;}#layerDDE5EB1980492BAD22E4D15A310DB34C .search_btn a {color: #fff!important;}#layerDDE5EB1980492BAD22E4D15A310DB34C .search_btn:hover {background-color: #000!important;border-color: #fff;color: #fff;}#layerDDE5EB1980492BAD22E4D15A310DB34C .search_btn:hover a {color: #fff!important;}

News and Events

 

Three products have been approved for marketing in Egypt, and Huiyu Pharmaceutical’s products are steadily advancing overseas.

May 17th. 2024
On February 20, 2024, Huiyu Pharmaceutical (stock code: 688553.SH) announced that the company’s products are docetaxel injection (specification: 20mg/1ml, 80mg/4ml), bendamustine hydrochloride for inj

To enrich the innovative drug industry chain, Huiyu Pharmaceutical leads the D round of financing of "TYK Medicines"

May 17th. 2024
In December 2023, Huiyu Pharmaceutical led the investment project - Zhejiang TYK Medicines Co., Ltd. (abbreviation: TYK Medicines), a leading company in the research and development of new cancer drug

The production line that has passed the US FDA on-site inspection has added new products

May 17th. 2024
 Recently, Huiyu Pharmaceutical received an on-site inspection report (EIR) issued by the U.S. Food and Drug Administration (hereinafter referred to as "U.S. FDA"), involving products including cyclo

Huiyu Pharmaceuticals once again passed the Finnish FIMEA-GMP certification.

May 17th. 2024
Recently, Huiyu Pharmaceutical received the GMP certificate issued by the Finnish Medicines Agency (FIMEA) and passed the Finnish FIMEA-GMP certification for the second time. This will help the compan

Huiyu Pharmaceuticals’ innovative dual-target small molecule drug HY-0002a IND has been accepted

May 17th. 2024
 Huiyu Pharmaceuticals announced on July 19, 2023 that Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Huiyu"), a wholly-owned subsidiary of Sichuan Huiyu Pharmac

HY-0002a, the first innovative dual-target small molecule drug, was approved for clinical trials

May 17th. 2024
On October 13, Huiyu Pharmaceuticals issued an announcement showing that its wholly-owned subsidiary Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Huiyu Haiyue"